Mice expressing A53T / A30P mutant alpha-synuclein in dopamine neurons do not display behavioral deficits
Keomanivong, C.; Schamp, J.; Tabakovic, E.; Thangavel, R.; Aldridge, G.; Pieper, A.; Narayanan, N.
Show abstract
Alpha-synuclein has been implicated in neurodegenerative diseases such as Parkinsons disease and Dementia with Lewy bodies, with A53T and A30P mutations shown to be disease-causing. It has been reported that transgenic mice with tyrosine hydroxylase promotor-driven expression of A53T / A30P mutant alpha-synuclein in dopamine neurons provide a useful preclinical model of these conditions by virtue of developing dopaminergic neuronal cell death and related behavioral deficits. Here, we report a lack of replication of this finding. Despite detecting robust overexpression of A53T / A30P mutant alpha-synuclein in dopamine neurons, we observed neither cell death or related behavioral deficits in these mice. Our results demonstrate that preclinical models of synucleinopathy need careful validation in the field.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.